Patents by Inventor Claus Oxvig
Claus Oxvig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11318158Abstract: A method is provided of decreasing or increasing the activity of a Pappalysin polypeptide by decreasing or increasing the level of interacting Pappalysin and stanniocalcin polypeptides. A method is also provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of a stanniocalcin polypeptide. Moreover, a method is provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of an agent capable of antagonizing interaction of a stanniocalcin polypeptide with a Pappalysin polypeptide.Type: GrantFiled: October 11, 2019Date of Patent: May 3, 2022Assignee: Aarhus UniversitetInventors: Claus Oxvig, Jakob Hauge Mikkelsen, Malene Runge Jepsen
-
Publication number: 20200261490Abstract: A method is provided of decreasing or increasing the activity of a Pappalysin polypeptide by decreasing or increasing the level of interacting Pappalysin and stanniocalcin polypeptides. A method is also provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of a stanniocalcin polypeptide. Moreover, a method is provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of an agent capable of antagonizing interaction of a stanniocalcin polypeptide with a Pappalysin polypeptide.Type: ApplicationFiled: October 11, 2019Publication date: August 20, 2020Inventors: Claus Oxvig, Jakob Hauge Mikkelsen, Malene Runge Jepsen
-
Patent number: 10392610Abstract: The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.Type: GrantFiled: August 22, 2014Date of Patent: August 27, 2019Assignee: Como Biotech ApSInventors: Claus Oxvig, Michael Toft Overgaard
-
Publication number: 20160151405Abstract: A method is provided of decreasing or increasing the activity of a Pappalysin polypeptide by decreasing or increasing the level of interacting Pappalysin and stanniocalcin polypeptides. A method is also provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of a stanniocalcin polypeptide. Moreover, a method is provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of an agent capable of antagonizing interaction of a stanniocalcin polypeptide with a Pappalysin polypeptide.Type: ApplicationFiled: May 12, 2014Publication date: June 2, 2016Inventors: Claus OXVIG, Jakob Hauge MIKKELSEN, Malene Runge JEPSEN
-
Publication number: 20150132770Abstract: The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.Type: ApplicationFiled: August 22, 2014Publication date: May 14, 2015Inventors: Claus Oxvig, Michael Toft Overgaard
-
Patent number: 9005949Abstract: The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.Type: GrantFiled: September 24, 2012Date of Patent: April 14, 2015Assignee: Como Biotech ApSInventors: Claus Oxvig, Michael Toft Overgaard
-
Publication number: 20150004632Abstract: The present Invention relates to a diagnostic and/or prognostic method comprising measurements of proMBP-complexes (major basic protein, PRG2). In particular the Invention relates to a diagnostic and/or prognostic method comprising measurements of the concentration of two or more proMBP-complexes. Further, the Invention relates to a method for determining the redox state In a pregnant female. Additionally, the Invention relates to a reaction kit comprising detection means for detecting two or more proMBP complexes, as well as to various uses of the reaction kit. Further, the invention relates to a method of diagnosis of preeclampsia by determining the ratio between proMBP protein in complex with PAPP-A and proMBP protein in complex with angiotensinogen (ATG).Type: ApplicationFiled: October 12, 2012Publication date: January 1, 2015Applicant: AARHUS UNIVERSITETInventors: Claus Oxvig, Soren Kloverpris
-
Publication number: 20140141456Abstract: PAPP-A2 is used as a marker for monitoring, predicting and diagnosing preeclampsia in pregnant women. PAPP-A2 levels in pregnant women with preeclampsia are higher than PAPP-A2 levels in normal pregnant women. This is especially true of PAPP-A2 levels that are measured later on in the pregnancy. PAPP-A2 levels may be measured early in pregnancy in order to predict the likelihood of the patient having preeclampsia. Preeclampsia may also be diagnosed at later gestational ages when the levels of PAPP-A2 are more pronounced than normal PAPP-A2 levels at the same gestational age. The present invention relates to methods of assessing, predicting and diagnosing preeclampsia as well as a kit-of-parts for assessing, predicting and diagnosing preeclampsia.Type: ApplicationFiled: August 30, 2013Publication date: May 22, 2014Applicant: Ansh Labs, LLCInventors: Ajay Kumar, Claus Oxvig, Gopal V. Savjani
-
Patent number: 8653020Abstract: The present invention relates in one embodiment to PAPP-A exosite(s) interactors such as antibodies which bind to a region comprising LNR3 of PAPP-A and efficiently inhibit proteolysis of IGFBP-4, but not -5. The region comprising LNR3 represents a substrate binding exosite, which can be targeted for selective proteolytic inhibition. Accordingly, the present invention relates in one embodiment to differential inhibition of natural protease substrates by exosite targeting.Type: GrantFiled: January 23, 2009Date of Patent: February 18, 2014Assignee: Aarhus UniversitetInventors: Claus Oxvig, Jakob Hauge Mikkelsen, Claus Gyrup Nielsen
-
Publication number: 20130095482Abstract: The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.Type: ApplicationFiled: September 24, 2012Publication date: April 18, 2013Inventors: Claus Oxvig, Michael Toft Overgaard
-
Publication number: 20130095569Abstract: The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.Type: ApplicationFiled: September 24, 2012Publication date: April 18, 2013Inventors: Claus Oxvig, Michael Toft Overgaard
-
Publication number: 20110091920Abstract: The present invention provides a method of diagnosing Down's syndrome, acute coronary syndrome or pre-eclampsia, or a predisposition to any of them, by a method comprising measuring the level of the human PAPP-A/proMBP complex in a body fluid sample.Type: ApplicationFiled: October 28, 2010Publication date: April 21, 2011Applicant: Como Biotech APSInventors: Claus Oxvig, Michael Toft Overgaard
-
Publication number: 20100310646Abstract: The present invention relates in one embodiment to PAPP-A exosite(s) interactors such as antibodies which bind to a region comprising LNR3 of PAPP-A and efficiently inhibit proteolysis of IGFBP-4, but not -5. The region comprising LNR3 represents a substrate binding exosite, which can be targeted for selective proteolytic inhibition. Accordingly, the present invention relates in one embodiment to differential inhibition of natural protease substrates by exosite targeting.Type: ApplicationFiled: January 23, 2009Publication date: December 9, 2010Inventors: Claus Oxvig, Jakob Hauge Mikkelsen, Claus Gyrup Nielsen
-
Publication number: 20090191640Abstract: Methods for screening for altered focal proliferation states in non-pregnant patients, which include detecting levels of pregnancy-associated plasma protein-A (PAPP-A), are described. Methods for identifying agents that alter the protease activity of PAPP-A, and pharmaceutical compositions and medical devices that include such agents also are described.Type: ApplicationFiled: February 23, 2009Publication date: July 30, 2009Inventors: Michael Toft Overgaard, Claus Oxvig, Cheryl A Conover
-
Publication number: 20070141669Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new protein with homology to pregnancy-associated plasma protein-A (PAPP-A). We denote this protein PAPP-A2. The cDNA encoding PAPP-A2 was derived from human placenta.Type: ApplicationFiled: June 13, 2006Publication date: June 21, 2007Inventors: Claus Oxvig, Michael Overgaard
-
Patent number: 7115382Abstract: Methods for screening for altered focal proliferation states in non-pregnant patients, which include detecting levels of pregnancy-associated plasma protein-A (PAPP-A) are described. Methods for identifying agents that alter the protease activity of PAPP-A, and pharmaceutical compositions and medical devices that include such agents are also described.Type: GrantFiled: March 15, 2000Date of Patent: October 3, 2006Assignees: Mayo Foundation for Medical Education and Research, Como Holdings APSInventors: Michael Toft Overgaard, Claus Oxvig, Cheryl A. Conover
-
Patent number: 7083940Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new protein with homology to pregnancy-associated plasma protein-A (PAPP-A). We denote this protein PAPP-A2. The cDNA encoding PAPP-A2 was derived from human placenta.Type: GrantFiled: October 22, 2001Date of Patent: August 1, 2006Assignee: Como Biotech ApSInventors: Claus Oxvig, Michael Toft Overgaard
-
Publication number: 20060148018Abstract: Methods for screening for altered focal proliferation states in non-pregnant patients, which include detecting levels of pregnancy-associated plasma protein-A (PAPP-A), are described. Methods for identifying agents that alter the protease activity of PAPP-A, and pharmaceutical compositions and medical devices that include such agents also are described.Type: ApplicationFiled: March 6, 2006Publication date: July 6, 2006Inventors: Michael Overgaard, Claus Oxvig, Cheryl Conover
-
Publication number: 20030124529Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new protein with homology to pregnancy-associated plasma protein-A (PAPP-A). We denote this protein PAPP-A2. The cDNA encoding PAPP-A2 was derived from human placenta.Type: ApplicationFiled: October 22, 2001Publication date: July 3, 2003Applicant: Como Biotech ApSInventors: Claus Oxvig, Michael Toft Overgaard